Cholestasis

• EMA withdrawal · 2021-12-17
  EMA Application withdrawn: Livmarli (Maralixibat chloride) — FGK Representative Service GmbH

  The EMA has withdrawn the application for Livmarli (maralixibat chloride) represented by FGK Representative Service GmbH.

• CLINICAL_TRIALS withdrawal · 2017-12-08
  Clinical Trial Update: Compassionate Use of Omegaven IV Fat Emulsion

  Compassionate-use access to Omegaven IV fat emulsion for cholestasis and liver disease is no longer available.

• CLINICAL_TRIALS withdrawal · 2016-06-21
  Clinical Trial Update: Enteral Fish Oil is Superior to Ursodeoxycholic Acid (UDCA) and Placebo for the Treatment of Cholestasis in Infants [Phase 2]

  The Phase 2 trial evaluating enteral fish oil for cholestasis in infants has been withdrawn.